Myopathy induced by HMG-CoA reductase inhibitors in rabbits: A pathological, electrophysiological, and biochemical study

Toxicology and Applied Pharmacology

Volumn 152, Issue 1, 1998, Pages 99-106

  Nakahara, Keiichi ^a   Kuriyama, Masaru ^a,b   Sonoda, Yoshito ^a   Yoshidome, Hiroaki ^a   Nakagawa, Hiroto ^a,b   Fujiyama, Jiro ^a,b   Higuchi, Itsuro ^a   Osame, Mitsuhiro ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b UNIVERSITY OF FUKUI   (Japan)

Author keywords

HMG CoA reductase inhibitor; Mitochondrial enzyme; Myotonia; Pathology; Respiratory chain; Rhabdomyolysis; Ubiquinone

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ELECTROPHYSIOLOGY; ENZYME ACTIVITY; HISTOPATHOLOGY; INTRAGASTRIC DRUG ADMINISTRATION; MUSCLE NECROSIS; MYOPATHY; MYOTONIA; NONHUMAN; RESPIRATORY CHAIN; RHABDOMYOLYSIS;

EID: 0031795348     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1998.8491     Document Type: Article

References (32)

1. Barka, T., and Anderson, P. J. (1962). Histochemical methods for acid phos-phatase using hexagonium pararosanilin as coupler. J. Histochem. Cyto-chem. 10, 741-753.
2. Berland, Y., Coponat, H. V., Durand, C., Baz, M., Laugier, R., and Musso, J. L. (1991). Rhabdomyolysis with simvastatin use. Nephron 57, 365-366.
3. Corpier, C. L., Jones, P. H., Suki, W. N., Lederer, E. D., Quinones, M. A., Schmidt, S. W., and Young, J. B. (1988). Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. JAMA 260, 239-241.
4. Dubowitz, V., and Brooke, M. H. (1973). Muscle Biopsy: A Modern Approach, pp. 20-33. Saunders, Philadelphia.
5. East, C., Alivizatos, P. A., Grundy, S. M., Jones, P. H., and Farmer, J. A. (1988). Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N. Engl. J. Med. 318, 47-48.
6. Folkers, K., Langsjoen, P., Willis, R., Richardson, P., Xia, L. J., Ye, C. Q., and Tamagawa, H. (1990). Lovastatin decreases coenzyme Q levels in humans. Proc. Natl. Acad. Sci. USA 87, 8931-8934.
7. Fukami, M., Maeda, N., Fukushige, J., Kogure, Y., Shimada, Y., Ogawa, T., and Tsujita, Y. (1993). Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits. Res. Exp. Med. 193, 263-273.
8. Goldstein, J. L., and Brown, M. S. (1990). Regulation of the mevalonate pathway. Nature 343, 425-430.
9. Hoeg, M. (1990). The HMG CoA reductase inhibitors. Curr. Opin. Lipidol. 1, 29-33.
10. Hunninghake, D. B. (1992). HMG CoA reductase inhibitors. Curr. Opin. Lipidol. 3, 22-28.
11. London, S. F., Gross, K. F., and Ringel, S. P. (1991). Cholesterol-lowering agent myopathy (CLAM). Neurology 41, 1159-1160.
12. Maltese, W. A., and Aprille, J. R. (1985). Relation of mevalonate synthesis to mitochondrial ubiquinone content and respiratory function in cultured neuroblastoma cells. J. Biol. Chem. 260, 11524-11529.
13. Mantell, G., Burke, M. T., and Staggers, J. (1990). Extended clinical safety profile of lovastatin. Am. J. Cardiol. 66, 11B-15B.
14. Nakahara, K., Kuriyama, M., Yoshidome, H., Nagata, K., Nagado, T., Nakagawa, M., Higuchi, I., and Osame, M. (1992). Experimental simvastatin-induced myopathy in rabbits. J. Neurol. Sci. 113, 114-117.
15. 2+ increase and cell damage in L6 rat myoblasts by HMG-CoA reductase inhibitors. Biochem. Biophys. Res. Commun. 202, 1579-1585.
16. Nobuyoshi, M., Saito, T., Takahira, H., Yamano, Y., and Kanazawa, T. (1984). Levels of coenzyme Q10 in biopsies of left ventricular muscle and influence of administration of coenzyme Q10. In Biochemical and Clinical Aspects of Coenzyme Q (K. Folkers and Y. Yamamura, Eds.), Vol. 4, pp. 221-229. Elsevier Science Publishers, Amsterdam.
17. Norman, D. J., Illingworth, D. R., Munson, J., and Hosenpud, J. (1988). Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. N. Engl. J. Med. 318, 46-47.
18. Ogasawara, S., Engel, A. G., Frens, D., and Mack, D. (1989). Muscle coenzyme Q deficiency in familial mitochondral encephalomyopathy. Proc. Natl. Acad. Sci. USA 86, 2379-2382.
19. Ohno, K., Tanaka, M., Sahashi, K., Ibi, T., Sato, W., Yamamoto, T., Takahashi, A., and Ozawa, T. (1991). Mitochondrial DNA deletions in inherited recurrent myoglobinuria. Ann Neurol. 29, 364-369, 1991.
20. Pierce, L. R., Wysowski, D. K., and Gross, T. P. (1990). Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 264, 71-75.
21. Reaven, P., and Witztum, J. L. (1988). Lovastatin, nicotinic acid, and rhabdomyolysis. Ann. Intern. Med. 109, 597-598.
22. Schalke, B. B., Schmidt, B., Toyka, K., and Hartung, H. P. (1992). Pravastatin-associated inflammatory myopathy. N. Engl. J. Med. 327, 649-650.
23. Seligman, A. M., Karnovsky, M. J., Wasserkrug, H. L., and Hanker, J. S. (1968). Non-droplet ultrastructural demonstration of cytochrome oxidase activity with a polymerizing osmiophilic reagent, diaminobenzidine (DAB). J. Cell Biol. 38, 1-14.
24. Serajuddin, A. T. M., Ranadive, S. A., and Mahoney, E. M. (1991). Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J. Pharm. Sci. 80, 830-834.
25. Smith, P. F., Eydelloth, R. S., Grossman, S. J., Stubbs, R. J., Schwartz, M. S., Germershausen, J. I., Vyas, K. P., Kari, P. H., and MacDonald, J. S. (1991). HMG-CoA reductase inhibitor-induced myopathy in the rat: Cyclosporine A interaction and mechanism studies. J. Pharmacol. Exp. Ther. 257, 1225-1235.
26. Sonoda, Y., Gotow, T., Kuriyama, M., Nakahara, K., Arimura, K., and Osame, M. (1994). Electrical myotonia of rabbit skeletal muscles by HMG-CoA reductase inhibitors. Muscle Nerve 17, 891-897.
27. Sottocasa, G. L., Kuylenstierna, B., Ernster, L., and Bergstrand, A. (1967). An electron transport system associated with the outer membrane of liver mitochondria. J. Cell Biol. 32, 415-438.
28. Srere, P. A. (1969). Citrate synthase. Methods Enzymol. 13, 3-11.
29. Tobert, J. A. (1988). Efficacy and long-term adverse effect pattern of lovastatin. Am. J. Cardiol. 62, 28J-34J.
30. Waclawik, A. J., Lindal, S., and Engel, A. G. (1993). Experimental lovastatin myopathy. J. Neuropathol. Exp. Neurol. 52, 542-549.
31. Wharton, D. C., and Tzagoloff, A. (1967). Cytochrome oxidase from beef heart mitochondria. Methods Enzymol. 10, 245-250.
32. Willis, R. A., Folkers, K., Tucker, J. L., Ye, C. Q., Xia, L. J., and Tamagawa, H. (1990). Lovastatin decreases coenzyme Q levels in rats. Proc. Natl. Acad. Sci. USA 87, 8928-8930.